Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 3, 2003, Pages 347-350

  Ohara, Koichi ^a   Tanabu, Shigeru ^a   Ishibashi, Kazuhisa ^a   Ikemoto, Keiko ^a   Yoshida, Kimiko ^a   Shibuya, Haruo ^a  

^a National Hospital Organization Hanamaki Hospital   (Japan)

Author keywords

Age; Cytochrome P450 2D6; Haloperidol; Polymorphism

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL;

ADULT; AGED; AGING; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; SCHIZOPHRENIA; VENOUS BLOOD;

EID: 0037402520     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00314-7     Document Type: Article

References (24)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, DSM-IV. 4th ed. 1994.
2. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3:2002;229-243.
3. Chang W.H., Jann M.W., Chiang T.S., Lin H.N., Hu W.H., Chien C.P. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population. Neuropsychobiology. 33:1996;12-16.
4. Chida M., Yokoi T., Kosaka Y., Chiba K., Nakamura H., Ishizaki T., Yokota J., Kinoshita M., Sato K., Inaba M., Aoki Y., Gonzalez F.J., Kamataki T. Genetic polymorphism of CYP 2D6 in the Japanese population. Pharmacogenetics. 9:1999;601-605.
5. Douglas A.M., Atchison B.A., Somogyi A.A., Olaf H. Drummer. Interpretation of a simple PCR analysis of the CYP 2D6(A) and CYP 2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics. 4:1994;154-158.
6. Forsman A., Öhman R. Applied pharmacokinetics of haloperidol in man. Curr. Ther. Res. 21:1977;396-410.
7. Heim M., Meyer U.A. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 336:1990;529-532.
8. Ingelman-Sundberg M., Evans W.E. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics. 11:2001;553-554.
9. Johansson I., Oscarson M., Yue Q.Y., Bertilsson L., Sjöqvist F., Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus, characterization of variant CYP 2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46:1994;452-459.
10. Morselli P.L., Bianchetti G., Dugas M. Haloperidol plasma level monitoring in neuropsychiatric patients. Ther. Drug Monit. 4:1982;51-58.
11. Nishida Y., Fukuda T., Yamamoto I., Azuma J. CYP 2D6 genotypes in a Japanese population, low frequencies of CYP 2D6 gene duplication but high frequency of CYP 2D6*10. Pharmacogenetics. 10:2000;567-570.
12. Roh H.K., Dahl M.L., Johansson I., Ingelman-Sundberg M., Cha Y.N., Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics. 6:1996;441-447.
13. Roh H.K., Chung J.Y., Oh D.Y., Park C.S., Svensson J.O., Dahl M.L., Bertilsson L. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol. 52:2001;265-271.
14. Rowell J.F., Hui S.M., Fairbairn A.F., Eccleston D. Total and free serum haloperidol levels in schizophrenic patients and the effect of age, thioridazine and fatty acid on haloperidol-serum protein binding in vitro. Br. J. Clin. Pharmacol. 11:1981;377-382.
15. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:1997;284-295.
16. Senda C., Yamamura Y., Kobayashi K., Fujii H., Minami H., Sasaki Y., Igarashi T., Chiba K. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. Br. J. Clin. Pharmacol. 52:2001;100-103.
17. Shibata N., Ohnuma T., Baba H., Shimada H., Takahashi T., Arai H. Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. Psychiatr. Genet. 9:1999;145-148.
18. Shimoda K., Morita S., Yokono A., Someya T., Hirokane G., Sunahara N., Takahashi S. CYP 2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther. Drug Monit. 22:2000;392-396.
19. Solomon K. Haloperidol and the geriatric patient, practical considerations. Ayd F.J. Haloperidol Update, 1950-1980. 1980;155-173 Ayd Medical Communications, Baltimore, MD.
20. Someya T., Suzuki Y., Shimoda K., Hirokane G., Morita S., Yokono A., Inoue Y., Takahashi S. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism, A preliminary study in a psychiatric population. Psychiatry Clin. Neurosci. 53:1999;593-597.
21. Steen V.M., Andreassen O.A., Daly A.K., Tefre T., Borresen A.L., Idle J.R., Gulbrandsen A.K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 5:1995;215-223.
22. Suzuki A., Otani K., Mihara K., Yasui N., Kaneko S., Inoue Y., Hayashi K. Effects of the CYP 2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 7:1997;415-418.
23. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharmacol. Ther. 23:1998;247-255.
24. Weber W.W. Populations and genetic polymorphisms. Mol. Diagn. 4:1999;299-307.